Cynata Therapeutics Ltd (STU:51S)
€ 0.128 0 (0%) Market Cap: 24.58 Mil Enterprise Value: 20.75 Mil PE Ratio: 0 PB Ratio: 5.88 GF Score: 42/100

Cynata Therapeutics Ltd ShareCafe 'Hidden Gems' Webinar Transcript

Oct 08, 2020 / NTS GMT
Ross Macdonald
Cynata Therapeutics Limited - CEO, MD

Thanks, Tim, and welcome, everybody, to the session today. The development of stem cells represents one of the major new waves in medicine, and quite simply stem cells are the body's own mechanisms for repair, recovery, and regeneration. And the ability to harness that allows us to approach the treatment of disease and recovery of diseases in a number of very, very important ways.

The particular type of stem cell that is receiving most attention at the moment is the Mesenchymal stem cell or MSC, and these cells represent a promising treatment for a broad range of diseases. And what we're now seeing is that clinical success in a range of clinical trials is creating a very large demand for product.

Because these are living cells or living drugs, the manufacture of such products is very complicated. So ultimately, commercial success requires a viable, scalable manufacturing solution that ensures a very consistent product.

And we've just seen recently some very informative news from the FDA about that particular issue. And the FDA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot